Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02524106 · ClinicalTrials.gov registry record · Phase 3
Bococizumab HIV Evaluation (B-HIVE) Study
A Phase 3 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT02524106: Clinical Trial Phase 3 study, sponsored by University of California, San Francisco.
NCT02524106 is a Phase 3 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 11 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02524106, a Phase 3 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
B-HIVE is a Phase 3, double blind, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of bococizumab 150 mg subcutaneously every 2 weeks to bococizumab placebo subcutaneously every 2 weeks for LDL-C lowering in HIV-infected subjects.
Primary Outcome
The primary endpoint for the study is the percent change from baseline in fasting LDL-C at week 12.
Interventions
- DRUG Placebo
- DRUG Bococizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
Why NCT02524106 stopped before completion
NCT02524106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02524106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02524106 about?
NCT02524106 is a clinical study titled "Bococizumab HIV Evaluation (B-HIVE) Study". B-HIVE is a Phase 3, double blind, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of bococizumab 150 mg subcutaneously every 2 weeks to bococizumab placebo subcutaneously every 2 weeks for LDL-C lowering in HIV-infected subjects.
What is the current status of trial NCT02524106?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2016-08. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02524106?
The interventions under investigation include: Placebo (DRUG), Bococizumab (DRUG).
Who is sponsoring clinical trial NCT02524106?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02524106's enrollment target sits among peer trials
11 1989th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia